KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Accumulated Expenses: 2009-2025

Historic Other Accumulated Expenses for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Sep 2025 value amounting to $5.0 million.

  • Acadia Pharmaceuticals' Other Accumulated Expenses fell 60.70% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 60.70%. This contributed to the annual value of $15.4 million for FY2024, which is 39.57% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Other Accumulated Expenses is $5.0 million, which was down 62.69% from $13.4 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Other Accumulated Expenses registered a high of $15.4 million during Q4 2024, and its lowest value of $986,000 during Q2 2022.
  • Over the past 3 years, Acadia Pharmaceuticals' median Other Accumulated Expenses value was $10.3 million (recorded in 2023), while the average stood at $10.4 million.
  • In the last 5 years, Acadia Pharmaceuticals' Other Accumulated Expenses tumbled by 65.33% in 2022 and then skyrocketed by 777.84% in 2023.
  • Acadia Pharmaceuticals' Other Accumulated Expenses (Quarterly) stood at $2.7 million in 2021, then increased by 0.82% to $2.7 million in 2022, then spiked by 307.53% to $11.0 million in 2023, then soared by 39.57% to $15.4 million in 2024, then plummeted by 60.70% to $5.0 million in 2025.
  • Its Other Accumulated Expenses was $5.0 million in Q3 2025, compared to $13.4 million in Q2 2025 and $9.3 million in Q1 2025.